AMGN:NGS-Amgen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 191.44

Change

0.00 (0.00)%

Market Cap

USD 121.99B

Volume

3.15M

Average Target Price

USD 208.53 (8.93%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The Company's business segment is human therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-12-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
GILD Gilead Sciences Inc.

N/A

USD 88.16B
BIIB Biogen Inc.

N/A

USD 63.82B
SHPG Shire plc

N/A

USD 52.74B
CELG Celgene Corporation

N/A

USD 49.00B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD 44.01B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 40.35B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 25.79B
BMRN BioMarin Pharmaceutical Inc.

N/A

USD 16.51B
INCY Incyte Corporation

N/A

USD 13.73B
GRFS Grifols S.A.

N/A

USD 13.17B

ETFs Containing AMGN

IBB iShares Nasdaq Biotechnol.. 9.30 % 0.47 %

N/A

USD 8.14B
BBH VanEck Vectors Biotech ET.. 8.94 % 0.35 %

N/A

USD 0.41B
BIB ProShares Ultra Nasdaq Bi.. 8.23 % 0.95 %

N/A

USD 0.28B
UBIO Proshares UltraPro Nasdaq.. 6.55 % 0.95 %

N/A

USD 0.03B
PBE Invesco Dynamic Biotech &.. 5.80 % 0.59 %

N/A

USD 0.28B
PJP Invesco Dynamic Pharmaceu.. 5.35 % 0.57 %

N/A

USD 0.51B
PILL Direxion Daily Pharmaceut.. 4.04 % 0.00 %

N/A

USD 4.01M
XLV SPDR Select Sector Fund -.. 3.62 % 0.14 %

N/A

USD 19.01B
LNGR Global X Longevity Themat.. 3.49 % 0.52 %

N/A

N/A
IYH iShares U.S. Healthcare 3.45 % 0.43 %

N/A

USD 2.45B
SHE SPDR Series Trust SSGA Ge.. 3.33 % 0.20 %

N/A

USD 0.35B
FHLC Fidelity MSCI Health Care.. 3.19 % 0.08 %

N/A

USD 1.61B
VHT Vanguard Health Care 3.18 % 0.10 %

N/A

USD 8.82B
HAU:CA Horizons Active US Divide.. 3.15 % 0.80 %

N/A

CAD 6.25M
BBP Virtus LifeSci Biotech Pr.. 3.04 % 0.84 %

N/A

USD 0.03B
QUAL iShares Edge MSCI USA Qua.. 2.73 % 0.15 %

N/A

USD 3.40B
QDYN FlexShares Quality Dynami.. 2.65 % 0.37 %

N/A

USD 0.04B
IXJ iShares Global Healthcare 2.59 % 0.47 %

N/A

USD 1.74B
JHMH John Hancock Multifactor .. 2.49 % 0.50 %

N/A

USD 0.06B
GMFL Invesco Multi-Factor Larg.. 2.21 % 0.25 %

N/A

USD 1.30M
RFDA RiverFront Dynamic US Div.. 1.71 % 0.52 %

N/A

USD 0.14B
XBI SPDR Series Trust S&P Bio.. 1.46 % 0.35 %

N/A

USD 4.06B
EGIF:CA Exemplar Growth and Incom.. 0.95 % 0.00 %

N/A

CAD 2.00M
CCOR Cambria Core Equity 0.00 % 1.21 %

N/A

USD 0.08B
ONEQ Fidelity Nasdaq Composite.. 0.00 % 0.21 %

N/A

USD 1.46B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.09% 75% C 79% C+
Dividend Return 3.04% 63% D 75% C
Total Return 13.12% 76% C 80% B-
Trailing 12 Months  
Capital Gain 9.14% 73% C 77% C+
Dividend Return 3.01% 63% D 72% C-
Total Return 12.15% 73% C 78% C+
Trailing 5 Years  
Capital Gain 67.96% 75% C 73% C
Dividend Return 17.09% 60% D- 74% C
Total Return 85.05% 77% C+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 11.14% 58% F 60% D-
Dividend Return 13.65% 60% D- 63% D
Total Return 2.51% 53% F 64% D
Risk Return Profile  
Volatility (Standard Deviation) 14.88% 93% A 76% C
Risk Adjusted Return 91.78% 98% A+ 82% B-
Market Capitalization 107.37B 100% A+ 100% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.85 2% F 7% F
Price/Book Ratio 8.22 12% F 11% F
Price / Cash Flow Ratio 2.95 8% F 34% F
Price/Free Cash Flow Ratio 12.26 8% F 35% F
Management Effectiveness  
Return on Equity 12.56% 88% B+ 75% C
Return on Invested Capital 20.54% 92% A- 86% B
Return on Assets 3.08% 92% A- 71% C-
Debt to Equity Ratio 209.75% 7% F 9% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector